Manufacturing, Biologics

WuXi Biologics Expands Manufacturing Capacity in Germany

June 01, 2023

WuXi Biologics is expanding its manufacturing capacity for drug substance and drug product at its sites in Leverkusen and Wuppertal, Germany.

Ramping Up Nucleic Acid Therapy Development

May 10, 2023

The market potential of nucleic acid-based therapies have been pushed into the spotlight following the success of the COVID-19 vaccines.

Optimizing the Manufacture of Emerging Therapies

May 01, 2023

Guidance for GMP manufacture of emerging therapies has evolved to accommodate innovation and the broader spectrum of products in development, but greater harmonization is still needed.

Diving Deep into Oral Biologics with Gregor Kawaletz (DCAT 2023)

April 20, 2023

Gregor Kawaletz, head of Oral Solid Dose Business Unit at Recipharm, discusses the immediate future of oral biologics

Avid Bioservices Expands Mammalian Cell Capacity

April 14, 2023

Avid Bioservices has launched new CGMP mammalian cell manufacturing suites at its Myford, Calif., facility.

New Expansion for BalanCD CHO Media Platform Portfolio for Bioprocessing

April 12, 2023

The BalanCD CHO media portfolio is designed to ensure maximized growth, viability, and productivity of CHO cell lines.

Ramping Up Development of Nucleic Acid Therapies

April 02, 2023

The COVID-19 vaccines opened the door to powerful market potential for other nucleic acid-based therapies.

Samsung Biologics to Build Plant 5 as Part of Capacity Expansion to Bio Campus II

March 21, 2023

Samsung Biologics plans to invest more than ₩1.9 trillion (US$1.5 billion) in the new Incheon, South Korea, facility, which will hold a manufacturing capacity of 180,000 L.

Sandoz to Build New Biologics Production Facility in Slovenia

March 17, 2023

Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.

Catalent Licenses Bhami Research Laboratory Technology for Biologics Formulation Development

March 17, 2023

Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.